AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33737438 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent GP attenders (5+ visits/year)
Number of subjects: 1464
Study 33737438 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed depression
Number of subjects: 1464
Study 33737438 — intervention group
Group type: COMPARATOR
Intervention: Low burden of depression symptoms (BDI score <13 or CES-D score <10)
Number of subjects: 1464
Study 36264568 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 54
Study 36264568 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (WBRT)
Number of subjects: 54
Study 32279541 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping™ (DCM)
Number of subjects: 726
Study 32279541 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 726
Study 33811457 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary HPV testing with reflex liquid-based cytology (LBC) upon a positive finding, screening interval of 48 months.
Number of subjects: 19009
Study 33811457 — intervention group
Group type: COMPARATOR
Intervention: Primary LBC testing, negative returns at 24 months for LBC and again at 48 months for exit screening.
Number of subjects: 19009
Study 32382859 — intervention group
Group type: EXPERIMENTAL
Intervention: PAIR technique
Number of subjects: 40
Study 32382859 — intervention group
Group type: COMPARATOR
Intervention: Catheterization technique
Number of subjects: 40
Study 35297709 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 30
Study 35297709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33216613 — intervention group
Group type: EXPERIMENTAL
Intervention: TRK (Thor-Ra-Nee-San-Tha-Kat) - 500 mg capsules, 2 capsules once daily before bed for 14 days
Number of subjects: 76
Study 33216613 — intervention group
Group type: COMPARATOR
Intervention: Naproxen - 250 mg tablets, 2 tablets twice a day after meals for 14 days
Number of subjects: 76
Study 33216613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Range of Motion (CROM)
Number of subjects: 76
Study 33216613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold (PPT)
Number of subjects: 76
Study 33067769 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Attendance (FA arm)
Number of subjects: 63
Study 33067769 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU arm)
Number of subjects: 63
Study 32830416 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbomer eye drops and polyethylene covers
Number of subjects: 24
Study 32830416 — intervention group
Group type: COMPARATOR
Intervention: Carbomer eye drops only
Number of subjects: 24
Study 34043272 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable infrared spectrometer for rapid point-of-care detection of COVID-19 markers in saliva
Number of subjects: 57
Study 35450891 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anaesthesia group (BIS 30-40)
Number of subjects: 854
Study 35450891 — intervention group
Group type: COMPARATOR
Intervention: Light anaesthesia group (BIS 45-55)
Number of subjects: 854
Study 33959989 — intervention group
Group type: EXPERIMENTAL
Intervention: NBSP
Number of subjects: 40
Study 33959989 — intervention group
Group type: COMPARATOR
Intervention: 3LP
Number of subjects: 40
Study 33959989 — intervention group
Group type: EXPERIMENTAL
Intervention: 3LP + ES
Number of subjects: 40
Study 33959989 — intervention group
Group type: EXPERIMENTAL
Intervention: NBSP + ES
Number of subjects: 40
Study 32128535 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade III central lumbar mobilization
Number of subjects: 21
Study 32128535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (light touch) intervention
Number of subjects: 21
Study 36192656 — intervention group
Group type: EXPERIMENTAL
Intervention: AI algorithm for assessing basic laparoscopic simulation training exercises
Number of subjects: 369
Study 34593124 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating ketone bodies (KBs) measured at 24 hours after reperfusion
Number of subjects: 369
Study 34593124 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating ketone bodies (KBs) measured at presentation
Number of subjects: 369
Study 34593124 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating ketone bodies (KBs) measured at 4-month follow-up
Number of subjects: 369
Study 32756176 — intervention group
Group type: EXPERIMENTAL
Intervention: Yangxinshi (YXS) tablet
Number of subjects: 90
Study 32756176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 35578267 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection and primary anastomosis with protective stoma (PS)
Number of subjects: 192
Study 35578267 — intervention group
Group type: COMPARATOR
Intervention: Resection and primary anastomosis without protective stoma (no PS)
Number of subjects: 192
Study 35578267 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints include postoperative mortality, unplanned reinterventions, incisional surgical site infection (SSI), organ/space SSI, wound disruption, anastomotic leak, operating time, length of hospital stay, stoma at 1 year after initial surgery, quality of life, costs and quality‐adjusted life years (QALYs).
Number of subjects: 192
Study 34148205 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P6
Number of subjects: 528
Study 34148205 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab
Number of subjects: 528
Study 32424430 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of PD-1 pathway inhibitors
Number of subjects: 216
Study 32424430 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of PD-1 pathway inhibitors
Number of subjects: 216
Study 34772330 — intervention group
Group type: EXPERIMENTAL
Intervention: High EPA + DHA diet (high or low sucrose)
Number of subjects: 90
Study 34772330 — intervention group
Group type: EXPERIMENTAL
Intervention: High ALA diet (high or low sucrose)
Number of subjects: 90
Study 34772330 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment
Number of subjects: 90
Study 34772330 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver PUFAs
Number of subjects: 90
Study 34772330 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF
Number of subjects: 90
Study 34772330 — intervention group
Group type: COMPARATOR
Intervention: Control diet (no EPA + DHA, low ALA, low sucrose)
Number of subjects: 90
Study 32348688 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST) with vitamin C (500 mg/day) and E (180 mg/day) supplementation
Number of subjects: 25
Study 32348688 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) with polydextrose (1 g/day)
Number of subjects: 25
Study 33635263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (ACE)
Number of subjects: 200
Study 33635263 — intervention group
Group type: COMPARATOR
Intervention: Sham ACE (SHAM)
Number of subjects: 200
Study 33027159 — intervention group
Group type: EXPERIMENTAL
Intervention: FAITH trial patients with displaced fractures
Number of subjects: 1079
Study 33027159 — intervention group
Group type: COMPARATOR
Intervention: HEALTH trial patients
Number of subjects: 1079
Study 616115972 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 84
Study 616115972 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release sodium fluoride (SR-NaF)
Number of subjects: 84
Study 616115972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 84
Study 34410384 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM) plus an annual In‐Clinic visit
Number of subjects: 595
Study 34410384 — intervention group
Group type: COMPARATOR
Intervention: In‐Clinic check‐ups alone (3-6 months)
Number of subjects: 595
Study 34410384 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM)
Number of subjects: 595
Study 33677172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with low-level laser therapy (ALLLT)
Number of subjects: 82
Study 33677172 — intervention group
Group type: COMPARATOR
Intervention: Sham ALLLT (control group)
Number of subjects: 82
Study 32652969 — intervention group
Group type: EXPERIMENTAL
Intervention: Alma Sana Bracelet Group
Number of subjects: 1445
Study 32652969 — intervention group
Group type: EXPERIMENTAL
Intervention: Star Bracelet Group
Number of subjects: 1445
Study 32652969 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 1445
Study 34198351 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with OloGen
Number of subjects: 40
Study 34198351 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with Mitomycin C (MMC)
Number of subjects: 40
Study 33795324 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 92
Study 33795324 — intervention group
Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 92
Study 32989888 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane (3 mL)
Number of subjects: 120
Study 32989888 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 35763326 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg or 100 mg
Number of subjects: 548
Study 35763326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study 33676595 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 227
Study 33676595 — intervention group
Group type: COMPARATOR
Intervention: Biotène
Number of subjects: 227
Study 36400376 — intervention group
Group type: EXPERIMENTAL
Intervention: ECST (recombinant fusion protein ESAT6-CFP10)
Number of subjects: 1085
Study 36400376 — intervention group
Group type: COMPARATOR
Intervention: TST (Tuberculin Skin Test)
Number of subjects: 1085
Study 36400376 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐SPOT.TB
Number of subjects: 1085
Study 36269935 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent/adjuvant ADT with PORT (n = 4,355)
Number of subjects: 7409
Study 36269935 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent/adjuvant ADT with WPRT (n = 3,049)
Number of subjects: 7409
Study 33313735 — intervention group
Group type: EXPERIMENTAL
Intervention: Active physical therapy clinical practice guidelines (CPG) implementation strategy using education, audit, and feedback model
Number of subjects: 3300
Study 33313735 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 3300
Study 34478611 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation task
Number of subjects: 254
Study 34478611 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 254
Study 34478611 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation and Control
Number of subjects: 254
Study 33781053 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib 1 mg/day
Number of subjects: 33
Study 33781053 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (physician's choice)
Number of subjects: 33
Study 33781053 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 33
Study 33781053 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 33
Study 33181674 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom combined with human anatomy web‐based learning system
Number of subjects: 89
Study 33181674 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom teaching
Number of subjects: 89
Study 36043569 — intervention group
Group type: EXPERIMENTAL
Intervention: F+Sn+HMC - 7,500 ppm F‐ / 15,000 ppm Sn2+
Number of subjects: 50
Study 36043569 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial acidulated phosphate fluoride gel (12,300 ppm F‐)
Number of subjects: 50
Study 36043569 — intervention group
Group type: EXPERIMENTAL
Intervention: F+HMC - 7,500 ppm F‐
Number of subjects: 50
Study 36043569 — intervention group
Group type: COMPARATOR
Intervention: Placebo - Hydroxypropyl Methylcellulose (HMC) gel
Number of subjects: 50
Study 36043569 — intervention group
Group type: COMPARATOR
Intervention: Control - no treatment
Number of subjects: 50
Study 36055770 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Spice Diet (MSD) at 3.3 g.d-1.2100 kcal-1
Number of subjects: 54
Study 36055770 — intervention group
Group type: EXPERIMENTAL
Intervention: High Spice Diet (HSD) at 6.6 g.d-1.2100 kcal-1
Number of subjects: 54
Study 36055770 — intervention group
Group type: COMPARATOR
Intervention: Low Spice Diet (LSD) at 0.5 g.d-1.2100 kcal-1
Number of subjects: 54
Study 34872531 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral to inpatient treatment (SRIT)
Number of subjects: 0
Study 34872531 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led SRIT treatment
Number of subjects: 0
Study 34872531 — intervention group
Group type: EXPERIMENTAL
Intervention: SRIT
Number of subjects: 0
Study 35565722 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat noodle meals
Number of subjects: 8
Study 35565722 — intervention group
Group type: COMPARATOR
Intervention: Rice noodle meals
Number of subjects: 8
Study 32220917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy meal replacement diet (MRP)
Number of subjects: 87
Study 32220917 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training
Number of subjects: 87
Study 32220917 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 87
Study 36254068 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Number of subjects: 200
Study 36254068 — intervention group
Group type: COMPARATOR
Intervention: Conventional culture methods
Number of subjects: 200
Study 32669026 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic exploration of the button followed by post-operative X-ray (Group B)
Number of subjects: 193
Study 32669026 — intervention group
Group type: COMPARATOR
Intervention: Post-operative X-ray to assess the position of the femoral button (Group A)
Number of subjects: 193
Study 32925778 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Ban-Xia-Xie-Xin-Decotion plus basic treatment
Number of subjects: 92
Study 32925778 — intervention group
Group type: COMPARATOR
Intervention: basic treatment only
Number of subjects: 92
Study 32666827 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES)
Number of subjects: 2
Study 32666827 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2
Study 34597298 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose regimen of 5-μg NVX-CoV2373
Number of subjects: 1288
Study 34597298 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose regimen of 25-μg NVX-CoV2373
Number of subjects: 1288
Study 34597298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1288
Study 32782008 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physical treatments (manual therapy, advice, education, exercise)
Number of subjects: 108
Study 615918822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab (anti-VEGF)
Number of subjects: 1183
Study 35108031 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression sleeves
Number of subjects: 307
Study 35108031 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 307
Study 32330315 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 18
Study 32330315 — intervention group
Group type: COMPARATOR
Intervention: Placebo PBMT
Number of subjects: 18
Study 32643454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal minoxidil 5% injections
Number of subjects: 20
Study 32643454 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-needling
Number of subjects: 20
Study 32643454 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (minoxidil + triamcinolone acetonide)
Number of subjects: 20
Study 32643454 — intervention group
Group type: COMPARATOR
Intervention: Negative control (observed patch)
Number of subjects: 20
Study 32949957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention (individual consultation, telephone follow-ups, self-help materials)
Number of subjects: 102
Study 32949957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 102
Study 32949957 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 34038455 — intervention group
Group type: COMPARATOR
Intervention: Information only (active control condition, n = 116)
Number of subjects: 451
Study 34038455 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonials addressing unspecified audience (arm 2, n = 112)
Number of subjects: 451
Study 34038455 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonials addressing employees (arm 3, n = 115)
Number of subjects: 451
Study 34038455 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonials addressing working university students (arm 4, n = 108)
Number of subjects: 451
Study 32475067 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg
Number of subjects: 0
Study 32475067 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 2.25 mg
Number of subjects: 0
Study 32475067 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg
Number of subjects: 0
Study 34260473 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper-perfusion index (HPi)
Number of subjects: 135
Study 34260473 — intervention group
Group type: EXPERIMENTAL
Intervention: HPi≥9.97
Number of subjects: 135
Study 34260473 — intervention group
Group type: EXPERIMENTAL
Intervention: HPi≥16.25
Number of subjects: 135
Study 34260473 — intervention group
Group type: COMPARATOR
Intervention: Non-EAD patients
Number of subjects: 135
Study 34260473 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving an HPi below target cut-off
Number of subjects: 135
Study 32900662 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 20-mg dexamethasone tablet (fasting)
Number of subjects: 36
Study 32900662 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 20-mg dexamethasone tablet (fed)
Number of subjects: 36
Study 32900662 — intervention group
Group type: COMPARATOR
Intervention: Five 4-mg dexamethasone tablets (reference)
Number of subjects: 36
Study 36302979 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneFolio® Pharmacogenomic Panel (4-week group)
Number of subjects: 0
Study 36302979 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneFolio® Pharmacogenomic Panel (psychiatrists’ patients)
Number of subjects: 0
Study 36302979 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneFolio® Pharmacogenomic Panel
Number of subjects: 0
Study 33944971 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia (5 mmol/l) with 20 mU [m2 BSA]‐1 min‐1 insulin (Eu20)
Number of subjects: 12
Study 33944971 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (17 mmol/l) with 20 mU [m2 BSA]‐1 min‐1 insulin (Hyper20)
Number of subjects: 12
Study 33944971 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (17 mmol/l) with 5 mU [m2 BSA]‐1 min‐1 insulin (Hyper5)
Number of subjects: 12
Study 32310158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbosacral immobilization using a custom-made pantaloon cast worn continuously for one week following a GC IDI of 25 mg of prednisolone acetate
Number of subjects: 12
Study 32310158 — intervention group
Group type: COMPARATOR
Intervention: GC IDI alone
Number of subjects: 12
Study 36064215 — intervention group
Group type: EXPERIMENTAL
Intervention: ISF schools
Number of subjects: 24
Study 36064215 — intervention group
Group type: COMPARATOR
Intervention: PBIS+SMH schools
Number of subjects: 24
Study 34390930 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive camouflage training
Number of subjects: 0
Study 34390930 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed camouflage training
Number of subjects: 0
Study 34390930 — intervention group
Group type: COMPARATOR
Intervention: Active control (no camouflage)
Number of subjects: 0
Study 35445052 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (initial dose of 70 or 100 mg three times a week)
Number of subjects: 68
Study 35445052 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin (subcutaneous injection for 24 weeks to maintain hemoglobin ranging from 100 to 120 g per liter)
Number of subjects: 68
Study 35445052 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 68
Study 35445052 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin
Number of subjects: 68
Study 32168216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalic elevation device inflation
Number of subjects: 60
Study 32168216 — intervention group
Group type: COMPARATOR
Intervention: Cephalic elevation device non-inflation (control)
Number of subjects: 60
Study 32168216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (inflation and non-inflation)
Number of subjects: 60
Study 36332136 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement (1 capsule/day for 8 weeks)
Number of subjects: 40
Study 36332136 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Number of subjects: 40
Study 36332136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32948471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction equation model of AMM using weight, sex, height, and handgrip strength as independent variables
Number of subjects: 1020
Study 32948471 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted AMM
Number of subjects: 1020
Study 32948471 — intervention group
Group type: COMPARATOR
Intervention: BIA-measured LM
Number of subjects: 1020
Study 32948471 — intervention group
Group type: COMPARATOR
Intervention: DXA-measured AMM
Number of subjects: 1020
Study 32737141 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic surgery (bariatric surgery)
Number of subjects: 73
Study 32737141 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 73
Study 32737141 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 73
Study 36202885 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression tights applied for 4 h (COMP)
Number of subjects: 22
Study 36202885 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet consumed every hour for 4 h (PLA)
Number of subjects: 22
Study 36202885 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 22